Top 100 global drug sales in the first half of 2019

Original: Voice of data The eagle strikes the sky, the fish flies the shallow bottom, and all kinds of frost compete for freedom Who is the master of ups and downs? It's fitting to start with Mao Zedong's poems The new drug market competes for a long and prosperous future Humaria, the first humanized antibody of Aberdeen, has been the global sales champion since 2012, making great strides like an eagle and reaping a lot But since last year, due to the competition of generic drugs, the sales of humria began to decline However, in 2017 and 2018, the sales of humria also reached US $18.827 billion and US $18.877 billion respectively, and the second place still could not be found In the first half of 2019, humria still occupies the first place in sales At this speed, the number one winner in 2019 is undoubtedly it again, amazing! On the one hand, Aberdeen filed a patent lawsuit against humria to delay the full invasion of generic drugs, on the other hand, he continued to expand the scope of its indications It can be boldly assumed that Humira will occupy the top position in the future The biggest bright spot in the list should be keytruda In the first half of 2019, the sales volume continued to soar to the position of Tanhua It can be said that in the competition of PD1 McAb, it has completely won over opdivo Although the sales performance of the latter is also very good, it's a pity that it's a winner and a loser! Imbruvica, as the first Btk inhibitor on the market, is not easy to achieve such a result compared with traditional tumor therapy drugs in the era of tumor immunotherapy Avastin, rituxan and Herceptin, the three anti-tumor monoclonal antibodies of Roche, are still in the top 10 position This child is not a thing in the pool It will turn into a dragon in case of storm Pfizer's anti breast cancer drugs ibrance, Roche's anti breast cancer monoclonal antibody perjeta and multiple sclerosis monoclonal antibody ocrevus also maintained a rapid growth momentum.